The increasingly complex rules that govern the global drug industry can be a major headache for drugmakers, with minor region to region variations often lengthening the time its takes to bring a drug to market.
Such delays can “cost” pharmaceutical and biotechnology firms millions in lost revenue which, given the competitive nature of the sector, can have a dramatic impact on performance.
Savvion and Patni, which specialize business process management (BPM) and trial regulatory and IT solutions, respectively, said the collaboration will help address these difficulties by “streamlining [clients’] drug development and clinical trial operations… while leveraging their existing information technology infrastructure.”
The combined offering will provide Patni's drug industry clients with access to Savvion's range of "BPM-enabled" modelling and optimisation solutions which, the firms claim, will improve the efficiency of clinical development operations.
Roy Devine, VP of consulting services at Patni, said that: “Drug trial managers face tremendous challenges,” explaining that “they must deal with expiring drug patents, dwindling drug pipelines, escalating costs of clinical trials, and increasingly stringent new regulatory guidelines that delay time to market.
“This new partnership will enhance Patni’s consulting practice by allowing us to offer Savvion’s pioneering BPM technology along with Patni’s regulatory and IT expertise to help our clients remain competitive.”
Pejman Makhfi, VP of solutions at Savvion also stressed the benefits of the partnership.
“Patni’s domain expertise in life sciences and Savvion’s track record for automating complex business processes, we can work together to give the drug industry BPM-enabled solutions to easily meet complex and ever-changing regulatory requirements and shorten the time to market for new drugs.”